文献速递免疫规划

CpG ODN或AddaVax佐剂化的肠道病毒D68灭活全病毒疫苗在小鼠中诱导强效保护性免疫

An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice.
PubMed 文献 · Vaccine · 2024-03-11

本研究在小鼠中比较不同病毒灭活试剂、疫苗佐剂和接种途径对肠道病毒D68灭活全病毒疫苗的优化效果。结果显示,BPL灭活疫苗联合CpG ODN或AddaVax佐剂可增强抗体应答和保护效果,而铝佐剂无此增强作用;鼻内接种虽诱导呼吸道IgA但保护效果弱于注射接种。

要点

  • BPL灭活全病毒疫苗联合CpG ODN或AddaVax可增强抗体应答和保护效果。
  • 铝佐剂未增强该灭活疫苗的抗体应答和保护效果。
  • 鼻内接种诱导呼吸道IgA但保护效果弱于注射接种。

核心结论

  • 以适当病毒灭活试剂和优化佐剂制备的注射用EV-D68灭活全病毒疫苗是有前景的EV-D68疫苗。

研究设计与样本

  • 在小鼠中研究最佳病毒灭活试剂、疫苗佐剂和接种途径以优化EV-D68灭活全病毒疫苗。

主要发现

  • 甲醛、β-丙内酯(BPL)和过氧化氢三种灭活试剂均有效诱导中和抗体。
  • BPL灭活全病毒疫苗联合CpG ODN或AddaVax(类MF59佐剂)时抗体应答增强,联合氢氧化铝(铝佐剂)时未增强。
  • 与抗体应答结果一致,联合CpG ODN或AddaVax时灭活全病毒疫苗对EV-D68攻击的保护效果增强,联合铝佐剂时未增强。
  • 鼻内接种灭活全病毒疫苗诱导呼吸道EV-D68特异性IgA抗体,但对EV-D68攻击的保护效果弱于注射接种。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enterovirus D68 (EV-D68), a pathogen that causes respiratory symptoms, mainly in children, has been implicated in acute flaccid myelitis, which is a poliomyelitis-like paralysis. Currently, there are no licensed vaccines or treatments for EV-D68 infections. Here, we investigated the optimal viral inactivation reagents, vaccine adjuvants, and route of vaccination in mice to optimize an inactivated whole-virion (WV) vaccine against EV-D68. We used formalin, β-propiolactone (BPL), and hydrogen peroxide as viral inactivation reagents and compared their effects on antibody responses. Use of any of these three viral inactivation reagents effectively induced neutralizing antibodies. Moreover, the antibody response induced by the BPL-inactivated WV vaccine was enhanced when adjuvanted with cytosine phosphoguanine oligodeoxynucleotide (CpG ODN) or AddaVax (MF59-like adjuvant), but not with aluminum hydroxide (alum). Consistent with the antibody response results, the protective effect of the inactivated WV vaccine against the EV-D68 challenge was enhanced when adjuvanted with CpG ODN or AddaVax, but not with alum. Further, while the intranasal inactivated WV vaccine induced EV-D68-specific IgA antibodies in the respiratory tract, it was less protective against EV-D68 challenge than the injectable vaccine. Thus, an injectable inactivated EV-D68 WV vaccine prepared with appropriate viral inactivation reagents and an optimal adjuvant is a promising EV-D68 vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Senpuku K, Kataoka-Nakamura C, Kunishima Y, et al. An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice. Vaccine. 2024. PMID: 38472067. doi:10.1016/j.vaccine.2024.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。